Interfering with long chain noncoding RNA ANRIL expression reduces heart failure in rats with diabetes by inhibiting...

Area of Science:

• Cardiovascular Biology
• Molecular Biology
• Diabetes Research

Background:

• Diabetes mellitus is a complex metabolic disorder with significant cardiovascular complications.
• Long-chain noncoding RNAs (lncRNAs) are emerging as key regulators in various biological processes, including diabetes.
• The role of lncRNA ANRIL in diabetic cardiomyopathy remains incompletely understood.

Purpose of the Study:

• To investigate the effect of long-chain noncoding RNA ANRIL on diabetes-induced cardiac dysfunction.
• To elucidate the underlying mechanism by which ANRIL influences diabetic myocardial injury.

Main Methods:

• A rat model of diabetes was established using streptozotocin injection.
• Rats were divided into normal, diabetes, control siRNA (siRNA-NC), and ANRIL siRNA groups.
• Key parameters assessed included ANRIL expression, cardiac function, inflammatory markers, cardiomyocyte apoptosis, and oxidative stress indices.

Main Results:

• ANRIL expression was significantly upregulated in the myocardial tissue of diabetic rats.
• Downregulation of ANRIL via siRNA improved cardiac function and reduced inflammatory factor levels.
• ANRIL silencing ameliorated myocardial pathological changes, decreased collagen deposition, reduced cardiomyocyte apoptosis, and lowered oxidative stress levels.

Conclusions:

• Upregulated ANRIL is associated with myocardial injury in diabetic rats.
• Silencing ANRIL demonstrates a protective effect against diabetic cardiomyopathy.
• ANRIL inhibition mitigates cardiac damage in diabetes by suppressing myocardial oxidative stress.